WO2020082495A1 - 一种AGEs抑制组合物及其应用、制备方法、制剂 - Google Patents
一种AGEs抑制组合物及其应用、制备方法、制剂 Download PDFInfo
- Publication number
- WO2020082495A1 WO2020082495A1 PCT/CN2018/117830 CN2018117830W WO2020082495A1 WO 2020082495 A1 WO2020082495 A1 WO 2020082495A1 CN 2018117830 W CN2018117830 W CN 2018117830W WO 2020082495 A1 WO2020082495 A1 WO 2020082495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- ages
- vitamin
- extract
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- bilberry extract 20 to 70 parts of ginkgo leaf extract, 40 to 75 parts of green tea extract, 1 to 20 parts of rosemary extract, 0.5 to 5 parts of vitamin B 1 and 0.5 to 5 parts of vitamin B 2 Servings, Vitamin B 6 0.5 to 5 servings.
- the diseases related to AGEs are diabetes, atherosclerosis, chronic kidney disease, liver disease, or neurodegenerative diseases.
- the injection preparation is an injection solution or a powder injection for injection.
- the results show that the above 7 samples can inhibit the generation of AGEs and have a degrading effect on the generated AGEs, thereby helping to delay and alleviate the occurrence of various diseases such as diabetes, atherosclerosis, chronic kidney disease, liver disease, and neurodegenerative diseases. development of.
- the health food formed by the combination of these compounds can provide new ideas and ways for preventing the occurrence and development of diseases related to AGEs.
- Bilberry Extract 150 Ginkgo biloba extract 63 Green tea extract 75 Rosemary extract 5 Vitamin B 1 5 Vitamin B 2 5 Vitamin B 6 5
- Preparation method Weigh and mix the raw materials.
- test results are as follows:
- the random number table method was used to randomly divide the subjects into an intervention group and a placebo group, and a three-month intervention trial was conducted.
- the people in the intervention group took the tablets of Example 4 with a dosage of 650 mg / tablet, 4 tablets per day.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Abstract
Description
原辅料名称 | 含量(重量份) |
越橘提取物 | 150 |
银杏叶提取物 | 63 |
绿茶提取物 | 75 |
迷迭香提取物 | 5 |
维生素B 1 | 5 |
维生素B 2 | 5 |
维生素B 6 | 5 |
原辅料名称 | 含量(重量份) |
越橘提取物 | 25 |
银杏叶提取物 | 110 |
绿茶提取物 | 25 |
迷迭香提取物 | 0.3 |
维生素B 1 | 0.1 |
维生素B 2 | 0.1 |
维生素B 6 | 10 |
原辅料名称 | 含量(重量份) |
越橘提取物 | 500 |
银杏叶提取物 | 15 |
绿茶提取物 | 125 |
迷迭香提取物 | 20 |
维生素B 1 | 10 |
维生素B 2 | 10 |
维生素B 6 | 0.1 |
原辅料 | 片剂 | 粉剂 | 口服液 |
越橘提取物 | 150mg | 75mg | 30mg |
银杏叶提取物 | 63mg | 50mg | 20mg |
绿茶提取物 | 75mg | 60mg | 40mg |
维生素B 1 | 5mg | 2mg | 0.5mg |
维生素B 2 | 5mg | 2mg | 0.5mg |
维生素B 6 | 5mg | 2mg | 0.5mg |
迷迭香提取物 | 5mg | 20mg | 1mg |
微晶纤维素 | 234mg | / | / |
羧甲淀粉钠 | 24mg | / | / |
交联聚维酮 | 24mg | / | / |
二氧化硅 | 8mg | / | / |
硬脂酸镁 | 6mg | / | / |
水溶性膳食纤维 | / | 1000mg | / |
抗性糊精 | / | 500mg | / |
木糖醇 | / | 1000mg | / |
果汁粉 | / | 1000mg | / |
纯化水 | / | / | 5000mg |
果汁 | / | / | 2000mg |
Claims (10)
- 一种AGEs抑制组合物,其特征在于,以重量份计,由如下原料组成:越橘提取物25~500份,银杏叶提取物15~110份,绿茶提取物25~125份,迷迭香提取物0.3~20份,维生素B 1 0.1~10份,维生素B 2 0.1~10份,维生素B 6 0.1~10份。
- 根据权利要求1所述的AGEs抑制组合物,其特征在于,以重量份计,由如下原料组成:越橘提取物30~150份,银杏叶提取物20~70份,绿茶提取物40~75份,迷迭香提取物1~20份,维生素B 1 0.5~5份,维生素B 2 0.5~5份,维生素B 6 0.5~5份。
- 根据权利要求1或2所述的AGEs抑制组合物,其特征在于,以重量份计,由如下原料组成:越橘提取物150份,银杏叶提取物63份,绿茶提取物75份,迷迭香提取物5份,维生素B 1 5份,维生素B 2 5份,维生素B 6 5份。
- 权利要求1至3中任一项AGEs抑制组合物在制备治疗、延缓或减轻AGEs相关疾病的药物或保健食品中的应用。
- 根据权利要求4所述的应用,其特征在于,所述AGEs相关疾病为糖尿病、动脉粥样硬化、慢性肾病、肝病或神经退行性疾病。
- 权利要求1至3中任一项AGEs抑制组合物的制备方法,其特征在于,将各原料混合。
- 一种AGEs抑制剂,其特征在于,包括权利要求1至3中任一项AGEs抑制组合物和保健食品学上可接受的辅料。
- 根据权利要求7所述的AGEs抑制剂,其特征在于,所述AGEs抑制剂的剂型为口服制剂或注射制剂。
- 根据权利要求8所述的AGEs抑制剂,其特征在于,所述口服制剂为片剂、粉剂、胶囊剂、颗粒剂、丸剂或口服液。
- 根据权利要求8所述的AGEs抑制剂,其特征在于,所述注射制 剂为注射液或注射用粉针剂。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018446538A AU2018446538B2 (en) | 2018-10-26 | 2018-11-28 | An AGEs inhibitory composition and its use, preparation method and formulation |
EP18934522.6A EP3677126A4 (en) | 2018-10-26 | 2018-11-28 | COMPOSITION OF AGE INHIBITORS, ITS USE, PROCESS OF PREPARATION AND ITS FORMULATION |
AU2021102625A AU2021102625A4 (en) | 2018-10-26 | 2021-05-17 | An AGEs inhibitory composition and its use, preparation method and formulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811257604.9A CN109090611B (zh) | 2018-10-26 | 2018-10-26 | 一种AGEs抑制组合物及其应用、制备方法、制剂 |
CN201811257604.9 | 2018-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020082495A1 true WO2020082495A1 (zh) | 2020-04-30 |
Family
ID=64869635
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/117830 WO2020082495A1 (zh) | 2018-10-26 | 2018-11-28 | 一种AGEs抑制组合物及其应用、制备方法、制剂 |
PCT/CN2018/124288 WO2020082587A1 (zh) | 2018-10-26 | 2018-12-27 | 越橘或其提取物在制备治疗、延缓或减轻AGEs相关疾病的药物或保健食品中的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/124288 WO2020082587A1 (zh) | 2018-10-26 | 2018-12-27 | 越橘或其提取物在制备治疗、延缓或减轻AGEs相关疾病的药物或保健食品中的应用 |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP3677126A4 (zh) |
CN (1) | CN109090611B (zh) |
AU (4) | AU2018446538B2 (zh) |
WO (2) | WO2020082495A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109090611B (zh) * | 2018-10-26 | 2022-01-07 | 汤臣倍健股份有限公司 | 一种AGEs抑制组合物及其应用、制备方法、制剂 |
CN111838674A (zh) * | 2020-07-30 | 2020-10-30 | 华中农业大学 | 一种具有抗糖功效的组合物及其应用 |
CN115317532A (zh) * | 2022-09-22 | 2022-11-11 | 杭州师范大学 | 迷迭香醇提取物在抑制乙二醛GO所诱导的糖基化终末产物AGEs的应用 |
CN115337334A (zh) * | 2022-09-22 | 2022-11-15 | 杭州师范大学 | 迷迭香醇提取物在抑制丙酮醛MGO所诱导的糖基化终末产物AGEs的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107427456A (zh) * | 2015-03-16 | 2017-12-01 | 博姿有限公司 | 抗自由基的局部用化妆品组合物 |
CN108514117A (zh) * | 2018-03-09 | 2018-09-11 | 北京素维生物科技有限公司 | 一种含有无异味油类的微囊粉组合物以及其制备工艺 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1275610C (zh) * | 2001-12-30 | 2006-09-20 | 深圳市海王眼之宝科技有限公司 | 防治近视和视疲劳的植物提取物组合物及其制备方法 |
JP2005220108A (ja) * | 2004-02-09 | 2005-08-18 | Meiji Univ | メイラード反応抑制剤及びメイラード反応の抑制方法 |
CN201512490U (zh) * | 2009-06-26 | 2010-06-23 | 广州汉方现代中药研究开发有限公司 | 一种越橘花色苷提取、分离、浓缩一体化装置 |
CN102742701A (zh) * | 2012-07-17 | 2012-10-24 | 北京绿源求证科技发展有限责任公司 | 一种预防视疲劳的食品养眼茶冲剂 |
CN105287690A (zh) * | 2014-06-06 | 2016-02-03 | 天津南开允公医药科技有限公司 | 一种欧洲越橘提取物及其制备方法 |
CN104592326A (zh) * | 2015-01-30 | 2015-05-06 | 南开大学 | 采用吸附树脂法从越橘粗提物制备高纯度花色苷的方法 |
CN109090611B (zh) * | 2018-10-26 | 2022-01-07 | 汤臣倍健股份有限公司 | 一种AGEs抑制组合物及其应用、制备方法、制剂 |
-
2018
- 2018-10-26 CN CN201811257604.9A patent/CN109090611B/zh active Active
- 2018-11-28 EP EP18934522.6A patent/EP3677126A4/en active Pending
- 2018-11-28 AU AU2018446538A patent/AU2018446538B2/en active Active
- 2018-11-28 WO PCT/CN2018/117830 patent/WO2020082495A1/zh active Search and Examination
- 2018-12-27 EP EP18934523.4A patent/EP3689361A4/en active Pending
- 2018-12-27 WO PCT/CN2018/124288 patent/WO2020082587A1/zh active Search and Examination
- 2018-12-27 AU AU2018446266A patent/AU2018446266B2/en active Active
-
2021
- 2021-05-17 AU AU2021102625A patent/AU2021102625A4/en not_active Ceased
- 2021-05-17 AU AU2021102622A patent/AU2021102622A4/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107427456A (zh) * | 2015-03-16 | 2017-12-01 | 博姿有限公司 | 抗自由基的局部用化妆品组合物 |
CN108514117A (zh) * | 2018-03-09 | 2018-09-11 | 北京素维生物科技有限公司 | 一种含有无异味油类的微囊粉组合物以及其制备工艺 |
Non-Patent Citations (1)
Title |
---|
YAN, QINGSONG ET AL.: "The Analysis of USA Herbal Dietary Supplements Market in 2013", MODERN CHINESE MEDICINE, vol. 16, no. 10, 31 October 2014 (2014-10-31), pages 842, XP055745132 * |
Also Published As
Publication number | Publication date |
---|---|
AU2021102622A4 (en) | 2021-07-08 |
EP3689361A4 (en) | 2021-06-02 |
AU2021102625A4 (en) | 2021-07-08 |
WO2020082587A1 (zh) | 2020-04-30 |
AU2018446266B2 (en) | 2023-11-09 |
AU2018446538A1 (en) | 2021-01-21 |
CN109090611B (zh) | 2022-01-07 |
EP3677126A1 (en) | 2020-07-08 |
AU2018446266A1 (en) | 2021-01-21 |
AU2018446538B2 (en) | 2022-12-08 |
EP3689361A1 (en) | 2020-08-05 |
EP3677126A4 (en) | 2021-06-23 |
CN109090611A (zh) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hajimonfarednejad et al. | Cinnamon: A systematic review of adverse events | |
De Oliveira et al. | Resveratrol and the mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view | |
Martel et al. | Antiaging effects of bioactive molecules isolated from plants and fungi | |
WO2020082495A1 (zh) | 一种AGEs抑制组合物及其应用、制备方法、制剂 | |
Stojanović et al. | Pomegranate peel extract ameliorates autoimmunity in animal models of multiple sclerosis and type 1 diabetes | |
Kones | Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition | |
JP2017214413A (ja) | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法 | |
Xie et al. | Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. | |
EP3188603A1 (en) | Green tea compositions | |
Jazani et al. | The potential role of saffron (Crocus sativus L.) and its components in oxidative stress in diabetes mellitus: A systematic review | |
JP2009298769A (ja) | 脂肪蓄積抑制用組成物 | |
Shetty et al. | Mechanisms and therapeutics of n-acetylcysteine: a recent update | |
JPWO2005082390A1 (ja) | 脂肪蓄積抑制剤 | |
CN106349318B (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
Lucida et al. | The assay of quercetin solid dispersion as a potential nephronprotector in acute renal failure induced mice | |
WO2021144446A1 (en) | Plant extract composition for the treatment of liver steatosis | |
Nagano et al. | Polyglycerol fatty acid ester contributes to the improvement and maintenance of water solubility of amorphous curcumin by suppressing the intermolecular interaction and the diffusion rate of curcumin | |
EP3603628A1 (en) | Composition for reducing weight and reducing body fat and pharmaceutical product and application thereof | |
JP2001048802A (ja) | 糖尿病に有効な健康補助食品およびその使用方法、並びに糖尿病に有効な食品配合剤 | |
KR20170026240A (ko) | 간 기능 개선용 건강기능식품 조성물 | |
Sratongfaeng et al. | Astaxanthin Supplementation Lowers Dietary Intake in Healthy Subjects. | |
US20230149412A1 (en) | Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity | |
KR20170026242A (ko) | 간 질환의 예방 또는 치료용 약학적 조성물 | |
KR102174613B1 (ko) | 밀랍으로 코팅된 봉독 비드를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물 | |
JP2009275026A (ja) | 膵臓リパーゼ活性阻害作用を有する組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018934522 Country of ref document: EP Effective date: 20200331 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18934522 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2018446538 Country of ref document: AU Date of ref document: 20181128 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |